In vitro interactions between apricitabine and other deoxycytidine analogues

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 2948-2953

  Bethell, R ^a,b   De Muys, J ^a   Lippens, J ^a   Richard, A ^a   Hamelin, B ^a   Ren, C ^a   Collins, P ^a  

^a Shire BioChem Inc   (Canada)

^b Research and Development   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; APRICITABINE; AVX 754; BCH 10618; DEOXYCYTIDINE KINASE; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SPD 754; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOSPHORYLATION; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG INTERACTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MALE; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34547637722     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01204-06     Document Type: Article

References (23)

1. Bethell, R. C., Y. S. Lie, and N. T. Parkin. 2005. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir. Chem. Chemother. 16:295-302.
2. Blaise, P., P. Clevenbergh, D. Vaira, M. Moutschen, and P. Dellamonica. 2002. HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin. Belg. 57:191-201.
3. Cahn, P., I. Cassetti, R. Wood, P. Phanuphak, L. Shiveley, R. C. Bethell, and J. Sawyer. 2006. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 20:1261-1268.
4. Cohen, C., C. Katlama, R. Murphy, J. Gathe, C. Brinson, G. Richmond, P. M. Girard, J. Fessel, A. Liappis, E. Puglia, B. Rodwick, J. Nadler, W. O'Brien, K. Arasteh, M. Otto, S. Viitanen-Erickson, and R. Levy. 2005. Antiretroviral activity and tolerability of Reverset (D-d4FC), a new fluorocytidine nucleoside analog, when used in combination therapy in treatment-experienced patients: results of phase 11b study RVT-203. Abstr. Third IAS, abstr. WeOaLB0103.
5. Delehanty, J., C. Wakeford, L. Hulett, J. Quinn, B. Mccreedy, M. Almond, D. Miralles, and F. Rousseau. 1999. A phase I/II randomized, controlled study of FTC versus 3TC in HIV-infected patients. Abstr. Sixth CROI, abstr. 16.
6. De Muys, J. M., H. Gourdeau, N. Ba-Nguyen, D. L. Taylor, P. S. Ahmed, T. Mansour, C. Locas, N. Richard, M. A. Wainberg, and R. F. Rando. 1999. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′- thiocytidine. Antimicrob. Agents Chemother. 43:1835-1844.
7. Erickson-Viitanen, S., J.-T. Wu, G. Shi, S. Unger, R. W. King, B. Fish, R. Klabe, R. Geleziunas, K. Gallagher, M. J. Otto, and R. F. Schinazi. 2003. Cellular pharmacology of D-D4FC, a nucleoside analog active against drug-resistant HIV. Antivir. Chem. Chemother. 14:39-47.
8. Furman, P. A., J. Fyfe, M. St. Clair, K. Weinhold, J. Rideout, G. Freeman, S. Lehrman, D. Bolognesi, S. Broder, and H. Mitsuya. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337.
9. Gao, W. Y., R. Agbaria, J. S. Driscoll, and H. Mitsuya. 1994. Divergent Anti-HIV activity and anabolic phosphorylation of 2′-3′- dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
10. Gish, R. G., N. W. Leung, T. L. Wright, H. Trinh, W. Lang, H. A. Kessler, L. Fang, L. H. Wang, J. Delehanty, A. Rigney, E. Mondou, A. Snow, and F. Rousseau. 2002. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob. Agents Chemother. 46:1734-1740.
11. Gu, Z., B. Allard, J. M. deMuys, J. Lippens, R. F. Rando, N. Ba-Nguyen, C. Ren, P. McKenna, D. L. Taylor, and R. C. Bethell. 2006. The in vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Antimicrob. Agents Chemother. 50:625-631.
12. Havlir, D. V., C. Tierney, G. H. Friedland, R. B. Pollard, L. Smeaton, J. P. Sommadossi, L. Fox, H. Kessler, K. H. Fife, and D. D. Richman. 2000. In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. 182:321-325.
13. Hoggard, P. G., S. D. Sales, S. Kewn, D. Sunderland, S. H. Khoo, C. A. Hart, and D. J. Back. 2000. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro. Antivir. Chem. Chemother. 11:353-358.
14. Hoggard, P. G., S. Kewn, M. G. Barry, S. H. Khoo, and D. J. Back. 1997. Effects of drugs on 2′,3′-dideoxy-2′,3′- didehydrothymidine phosphorylation in vitro. Antimicrob. Agents Chemother. 41:123-126.
15. Hoggard, P., S. Khoo, M. Barry, and D. Back. 1996. Intracellular metabolism of zidovudine and stavudine in combination. J. Infect. Dis. 174:671-672.
16. Ho, H. T., and M. J. Hitchcock. 1989. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against HIV. Antimicrob. Agents Chemother. 33:844-849.
17. Holdich, T., L. A. Shiveley, and J. Sawyer. 2007. Effect of lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 51:2943-2947.
18. Kewn, S., G. J. Veal, P. G. Hoggard, M. G. Barry, and D. J. Back. 1997. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54:589-595.
19. Molina, J. M., G. Peytavin, S. Perusat, C. Lascoux-Combes, D. Sereni, W. Rozenbaum, and G. Chene. 2004. Pharmacokinetics of emtricitabine, didanosine, and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Med. 5:99-104.
20. Quan, Y., B. G. Brenner, M. Oliveira, and M. A. Wainberg. 2003. Lamivudine can exert a modest antiviral effect against HIV type 1 containing the M184V mutation. Antimicrob. Agents Chemother. 47:747-754.
21. Ray, A. S. 2005. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev. 7:113-125.
22. U.S. Department of Health and Human Services. 2006. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. U.S. Department of Health and Human Services, Washington, DC. [Online.] http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
23. Yuen, G. J., Y. Lou, N. F. Bumgarner, J. P. Bishop, G. A. Smith, V. R. Otto, and D. D. Hoelscher. 2004. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 mg once daily and 150mg twice daily. Antimicrob. Agents Chemother. 48:176-182.